Vise Technologies Inc. Increases Position in Biogen Inc. $BIIB

Vise Technologies Inc. raised its position in Biogen Inc. (NASDAQ:BIIB) by 93.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,415 shares of the biotechnology company’s stock after purchasing an additional 2,616 shares during the quarter. Vise Technologies Inc.’s holdings in Biogen were worth $953,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rothschild Investment LLC raised its position in Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares during the period. Advisory Services Network LLC increased its position in shares of Biogen by 3.9% during the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares during the period. Davis Investment Partners LLC increased its position in shares of Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after acquiring an additional 71 shares during the period. Optas LLC increased its position in shares of Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 73 shares during the period. Finally, CIBC Private Wealth Group LLC increased its position in shares of Biogen by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 89 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

BIIB has been the topic of a number of recent research reports. The Goldman Sachs Group upped their price objective on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Mizuho upped their price objective on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and a consensus target price of $217.26.

Biogen Stock Up 3.4%

Shares of NASDAQ BIIB opened at $199.10 on Wednesday. The business has a 50-day moving average of $187.94 and a two-hundred day moving average of $183.85. The company has a market capitalization of $29.40 billion, a price-to-earnings ratio of 21.36 and a beta of 0.20. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts forecast that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.